Patent Exclusivity Health Checks for Small Molecules: Are Your U.S. Patents Ready to Maximize ROI?
August 11, 2020
Webinar
Strafford Publications
As part of Strafford Publications' webinar series, Finnegan partners Mark Feldstein, Tom Irving, Jill MacAlpine, Barbara Rudolph, and David Weingarten will provide guidance to patent counsel on the essentials of patent exclusivity that are in critical need of independent checking. The panel will discuss crucial health checks on U.S. patent exclusivity for small molecules in Phase II efficacy trials and proceedings through large-scale randomized Phase III clinical trials, submission of the NDA, and subsequent approval and marketing. For more information, or to register, please see Strafford’s website.
Tags
drugs, enforcement, ex parte reexamination, inventorship, new drug application (NDA), Orange Book, patent exclusivity, Patent Trial and Appeal Board (PTAB), supplemental examination, United States Court of Appeals for the Federal Circuit (CAFC)
